Clinical Trials
84 trialsA Study of PF-08046049/SGN-BB228 in Advanced Melanoma and Other Solid Tumors
Seagen Inc.
Study of CTX-471 as a Monotherapy or in Combination With Pembrolizumab in Patients Post PD-1/PD-L1 Inhibitors in Metastatic or Locally Advanced Malignancies
Compass Therapeutics
LuPARP
Vastra Gotaland Region
STEALTH-001
KaliVir Immunotherapeutics
A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors
IDEAYA Biosciences
A Study to Assess a PI3Kδ Inhibitor (IOA-244) in Patients With Metastatic Cancers
iOnctura
Study of Nanrilkefusp Alfa Alone and With Pembrolizumab in Adult Patients With Advanced/Metastatic Solid Tumors
Sotio Biotech Inc.
A Phase 1 Clinical Study of NXP900 in Subjects With Advanced Cancers
Nuvectis Pharma, Inc.
Anti-Mesothelin TNaive/SCM hYP218 (TNhYP218) CAR T Cells in Participants With Mesothelin-Expressing Solid Tumors Including Mesothelioma
National Institutes of Health Clinical Center (CC)
MESO-PRIME
Royal Marsden NHS Foundation Trust
A Study of SGN-MesoC2 in Advanced Solid Tumors
Seagen Inc.
A Study of Safety and Efficacy of KFA115 Alone and in Combo With Pembrolizumab in Patients With Select Advanced Cancers
Novartis
KZR-261 in Subjects With Advanced Solid Malignancies
Kezar Life Sciences, Inc.
Phase 1 Study of MRTX1719 in Solid Tumors With MTAP Deletion
Bristol-Myers Squibb
Naptumomab Estafenatox in Combination With Durvalumab in Subjects With Selected Advanced or Metastatic Solid Tumor, Including a Cohort Expansion in Esophageal Cancer.
NeoTX Therapeutics Ltd.
A Study of HFB200301 as a Single Agent and in Combination With Tislelizumab in Adult Patients With Advanced Solid Tumors
HiFiBiO Therapeutics
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099318 in Participants With Advanced Solid Tumors
Incyte Corporation
A Phase 1a/1b Study of ACTM-838 in Patients With Advanced Solid Tumors
Actym Therapeutics, Inc.
A Phase I Study of IAG933 in Patients With Advanced Mesothelioma and Other Solid Tumors
Novartis
Arginase Inhibitor INCB001158 as a Single Agent and in Combination With Immune Checkpoint Therapy in Patients With Advanced/Metastatic Solid Tumors
Incyte Corporation
MK-3475-A17
Merck Sharp & Dohme LLC
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Advanced Solid Tumors
Incyte Corporation
Phase I Dose-Escalation Study Of Azacitidine In Combination With Temozolomide
Columbia University
Using a Targeted Cancer Vaccine (Galinpepimut-S) With Immunotherapy (Nivolumab) in Mesothelioma
Memorial Sloan Kettering Cancer Center
RAPTOR
Turnstone Biologics, Corp.
Study of ASTX295 in Patients With Solid Tumors With Wild-Type p53
Taiho Oncology, Inc.
Effects of Itraconazole and Rifampin on the Blood Tazemetostat Levels
Ipsen
Sym024 Monotherapy and in Combination With Sym021 in Patients With Advanced Solid Tumor Malignancies
Symphogen A/S
AROG4-01-01
Aromics Therapeutics
Study of MT-8421 as Monotherapy and in Combination With Nivolumab in Patients With Selected Advanced Solid Cancer Types
Molecular Templates, Inc.
Study of NGM831 as Monotherapy and in Combination With Pembrolizumab or Pembrolizumab and NGM438 in Advanced or Metastatic Solid Tumors
NGM Biopharmaceuticals, Inc
A Study of BGC515 Capsules in Subjects With Advanced Solid Tumors
BridGene Biosciences Inc.
GL-ONC1 Administered Intravenously Prior to Surgery to Patients With Solid Organ Cancers
University of California, San Diego
PF-06952229 Treatment in Adult Patients With Advanced Solid Tumors
Pfizer
GPC3/Mesothelin-CAR-γδT Cells Against Cancers
Second Affiliated Hospital of Guangzhou Medical University
Study of NGM438 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumors
NGM Biopharmaceuticals, Inc
Intratumor Injection of Anti-Mesothelin Immunotoxin LMB-100 With Ipilimumab in Malignant Mesothelioma
National Institutes of Health Clinical Center (CC)
MpeTK01
Candel Therapeutics, Inc.
DUET-2
Xencor, Inc.
First in Human Phase 1 Study of AG01 Anti-Progranulin/GP88 Antibody in Advanced Solid Tumor Malignancies
A&G Pharmaceutical Inc.
Study of Safety, Pharmacokinetic and Efficacy of APG-5918 in Advanced Solid Tumors or Lymphomas
Ascentage Pharma Group Inc.
Mesothelin-Targeted Immunotoxin LMB-100 in People With Malignant Mesothelioma
National Institutes of Health Clinical Center (CC)
Study of the Glutaminase Inhibitor CB-839 in Solid Tumors
Calithera Biosciences, Inc
Bosutinib in Combination With Pemetrexed in Patients With Selected Metastatic Solid Tumors
Augusta University
Phase I Trial HIPEC With Nal-irinotecan
Stony Brook University
A Study of the Safety, Tolerability and Pharmacokinetics of ABBV-368 as a Single Agent and Combination in Subjects With Locally Advanced or Metastatic Solid Tumors
AbbVie
A Study of Budigalimab (ABBV-181) in Participants With Advanced Solid Tumors
AbbVie
A Study of LY3023414 in Participants With Advanced Cancer
Eli Lilly and Company
A Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IPI-549
Infinity Pharmaceuticals, Inc.
Study of Cytoreductive Surgery and Hyperthermic Intraoperative Chemotherapy With Pemetrexed and Cisplatin for MPM
Baylor College of Medicine